Glutamate Modulators for Treatment-Resistant OCD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anxiety disorders, particularly obsessive-compulsive disorder (OCD), often fail to provide complete relief for patients, and existing pharmacological therapies are associated with adverse effects and limited efficacy for those who do not respond to serotonin reuptake inhibitors (SRIs).
Innovation Solution
Administering glutamate modulators such as riluzole, N-acetylcysteine, or β-lactam antibiotics to normalize glutamate levels, enhance glutamate uptake, or attenuate presynaptic glutamate release, either alone or in combination with SRIs, to enhance treatment efficacy for anxiety disorders, including OCD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serotonin reuptake inhibitors (SRIs) are used to treat anxiety disorders and OCD, then some patients experience symptom relief, but a subset of patients experience minimal relief and the treatments are associated with adverse effects
Solution Approach 1:
The patent changes the neurochemical parameter being targeted from serotonin to glutamate. By using glutamate modulators instead of SRIs, the treatment addresses a different neurochemical system, thereby avoiding the adverse effects associated with SRI while potentially improving effectiveness for treatment-resistant patients
Solution Approach 2:
The patent introduces glutamate modulators as intermediary substances that indirectly affect OCD and anxiety symptoms by modulating glutamatergic neurotransmission. This intermediary approach allows treatment of the same disorders through a different biochemical pathway, avoiding direct side effects of SRIs
2Reliability
If SRIs are used as first-line treatment for OCD, then many patients show improvement, but treatment-resistant patients require augmentation strategies that do not eliminate symptoms and introduce additional adverse effects
Solution Approach 1:
The patent switches from serotonin-based treatment to glutamate-based treatment, fundamentally changing the neurochemical parameter. This single-parameter change replaces complex augmentation strategies with direct glutamate modulation, simplifying the treatment regimen while addressing treatment resistance
Solution Approach 2:
The patent extracts the glutamatergic component from the treatment approach, separating it from the failed serotonin-based augmentation strategies. By focusing specifically on glutamate modulation, the patent eliminates the need for complex multi-drug regimens
3Reliability
If neuroleptic medications are added to SRI therapy for OCD augmentation, then treatment effectiveness improves, but adverse effects increase when used chronically
Solution Approach 1:
The patent changes the target neurochemical system from serotonin to glutamate, using glutamate modulators that do not produce the chronic adverse effects associated with neuroleptics. This parameter change maintains treatment effectiveness while eliminating harmful side effects
Data Source
AI summary
Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.